论文部分内容阅读
目的:观察不同疗程化疗联合放疗治疗中晚期鼻咽癌的临床疗效。方法:选择经病理检查证实的鼻咽癌95例,随机分为观察组52例和对照组43例。对照组采用紫杉醇加顺铂的新辅助化疗2个疗程后单纯放疗,观察组新辅助化疗2个疗程后在放疗的同时继续化疗4个疗程,比较两组临床疗效和不良反应发生情况。结果:观察组鼻咽病灶和颈部淋巴结病灶缓解率分别为94.2%(49/52)和84.6%(44/52),均显著高于对照组的79.1%(34/43)和69.8%(30/43)(P<0.05)。观察组白细胞计数下降发生率96.2%(50/52),虽然显著高于对照组的55.8%(24/43)(P<0.05),但经对症处理后均迅速缓解;两组口咽黏膜反应、消化道反应以及腮腺炎和中耳炎发生率均差异不显著(P>0.05)。结论:多疗程新辅助化疗联合放疗治疗中晚期鼻咽癌的临床疗效较好。
Objective: To observe the clinical effects of different courses of chemotherapy combined with radiotherapy in the treatment of advanced nasopharyngeal carcinoma. Methods: 95 cases of nasopharyngeal carcinoma confirmed by pathology were randomly divided into observation group (52 cases) and control group (43 cases). Control group with paclitaxel plus cisplatin neoadjuvant chemotherapy after 2 courses of radiotherapy alone, the observation group of neoadjuvant chemotherapy after 2 courses of radiotherapy while continuing chemotherapy for 4 courses, the two groups were compared the clinical efficacy and adverse reactions. Results: The remission rates of nasopharyngeal lesions and cervical lymph nodes in the observation group were 94.2% (49/52) and 84.6% (44/52), respectively, which were significantly higher than those in the control group (79.1%, 34/43) and 69.8% 30/43) (P <0.05). The incidence of white blood cell count decrease in the observation group was 96.2% (50/52), which was significantly higher than that in the control group (55.8%, 24/43) (P <0.05) , Digestive tract reaction and the incidence of mumps and otitis media were not significantly different (P> 0.05). Conclusion: The multi-course neoadjuvant chemotherapy combined with radiotherapy in the treatment of advanced nasopharyngeal carcinoma has a good clinical efficacy.